Acute Coronary Syndrome
- Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
- Acute Myocardial Infarction Toolkit
- Diabetes Optimal Care Cardiovascular Risk Reduction (DOC-CARE) EHR “MY CHART”
- Heart Disease: Resources for Individuals and Patients
- Acute coronary syndromes
- 2020 ESC NSTE-ACS Guidelines: Evolving Approaches and Recommendations
- 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
- IMPROVE-IT Trial: ACC 2015
- 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Atherothrombosis
- DAPT PEGASUS and TRA 2P Trials Primary Efficacy and Safety Outcomes
- 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
- Selection of a Suitable Patient Population for New Antiplatelet Therapy From the Large Clinical Trial Database of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis in Myocardial Infarction 50 (TRA-2P–TIMI50) Trial
- Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
- Coagulation factor Xa (recombinant), inactivated-zhzo Prescribing Information
- 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee
- Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
- Management of bleeding in patients receiving direct oral anticoagulants
- Resources to support Joint Commission Accredited organizations implementation of: Reduce the likelihood of patient harm associated with the use of anticoagulant therapy
- Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Cardiac Imaging
- 2021AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain
- Selecting the optimal cardiac stress test
- Cardiac Stress Testing: Choosing the Right Test and When
Dyslipidemia
- Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial
- An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease
- ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
- HPS3/TIMI55-REVEAL: Long-term Safety and Efficacy of Anacetrapib
- ROSE Study: Obicetrapib and High-Intensity Statin Therapy
- Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
- 2018 Guideline on the Treatment of High Blood Cholesterol: Education for Clinicians
- Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention
- Bempedoic Acid for LDL-C Lowering: What Do We Know?
- Heart Disease and Stroke Statistics—2021 Update
- Identification of female-specific risk enhancers throughout the lifespan of women to improve CVD prevention
- The ABCs of Primary Cardiovascular Prevention: 2019 Update
- Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease
- Improving the Cardiovascular Health of Women in the Nation
- Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- Epidemiology of Dyslipidemia and Economic Burden on the Healthcare System
- Prescribing Information for Alirocumab
- Prescribing Information for Evolocumab
- Diabetic Dyslipidemia: Causes and Consequences
- 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- ACC Statin Intolerance Tool
- 2017 NLA Expert Panel on Treatment with PCSK9 Inhibitors
- 2017 NLA Expert Panel on Treatment with PCSK9 Inhibitors – Infographic
- PCSK9 Inhibitor Access Barriers – Issues and Recommendations
- Current Indications, Cost, and Clinical Use of Anti-PCSK9 Monoclonal Antibodies
- NLA Recommendations for Patient-Centered Management of Dyslipidemia
- Patient Information: Reduce Your Risk of Heart Attack and Stroke
- High Cholesterol Educational Materials for Patients
Familial Chylomicronemia Syndrome (FCS)
- Qualitative development of the PROMIS Profile v1.0-Familial Chylomicronemia Syndrome (FCS) 28
- Burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study
- Understanding FCS – for Patients
- About FCS
- 2015-2020 Dietary Guidelines
- Medications that Increase Triglycerides
- FCS References
- What is FCS?
Familial Hypercholesterolemia (FH)
- Diagnostic Criteria for Familial Hypercholesterolemia
- Familial Hypercholesterolemia: Cardiovascular Risk Stratification and Clinical Management
- Learning About Familial Hypercholesterolemia
Heart Failure (HF)
- Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week
- Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
- Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
- Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
- Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial
- Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
- PARADIGM-HF Trial of Sacubitril/Valsartan
- Ivabradine in Heart Failure
- A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock
- Cardiac Calcitropes, Myotropes, and Mitotropes
- Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials
- Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
- Heart Failure: Patient Education
Hypertension
- CDC Facts About Hypertension
- Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparison, Reflections, and Recommendations
- 2017 Guideline for High Blood Pressure in Adults
- High Blood Pressure Information for Patients
- Treatment of resistant hypertension
- Million Hearts® Hypertension Control: Action Steps for Clinicians
- Systolic Blood Pressure Intervention Trial (SPRINT)
Hypertriglyceridemia
- Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
- Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results
- REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
- 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee
- Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association
- National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk
- Infographic: Use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk
- REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. AHA 2018.
- Hypertriglyceridemia and atherosclerosis
- Hypertriglyceridemia and omega-3 fatty acids: Their often-overlooked role in cardiovascular disease prevention
- Fish and Omega-3 Fatty Acids
Hypertrophic Cardiomyopathy (HCM)
- 2024 AHA/ACC/Multisociety Guideline for the Management of HCM
- Mavacamten Prescribing Information
- Mavacamten REMS (Risk Evaluation and Mitigation Strategy)
- Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
- VALOR-HCM: A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
- Risk Stratification in HCM
- Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review
- Associations of Race and Ethnicity With Presentation and Outcomes of Hypertrophic Cardiomyopathy
- Patient Information: Hypertrophic Cardiomyopathy (HCM)
- Hypertrophic Cardiomyopathy Association (HCMA)
- HCM Patient Discussion Checklist
- Patient Information: Hypertrophic Cardiomyopathy (HCM)
- Encouraging Share Decision Making in HCM
- Patient Info: HCM Action Plan
- Patient Info: HCM Fact Sheets
- Patient Info: HCM Genetic Testing
- Patient Info: Hypertrophic Cardiomyopathy
Lipoprotein (a) [Lp(a)]
- A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice
- Use of Lipoprotein(a) in Clinical Practice Infographic
- Patient Resource: What is Lipoprotein(a)?
- Patient Resource: Treating High Lp(a)
- Assessing Risk: Infographic on Lp(a) Screening
- Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)
- Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease
Venous Thromboembolism (VTE)
- American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
- Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report
- What is Venous Thromboembolism (VTE)?
- Antithrombotic Therapy for VTE Disease
- Wells’ Criteria for Pulmonary Embolism